Q1 2025 Earnings Conference Call May 9, 2025 4:30 PM ET. Company Participants. Bernie Hertel - Head of Investor Relations Punit Dhillon - Presi ...

A panelist discusses how a new drug combination of doravirine and islatravir was compared to a standard bictegravir-based ...

Net loss for the three months ended March 31, 2025, totaled $11.1 million, with non-cash share-based compensation expense of ...

People are buying semaglutide and tirzepatide, the key ingredients in Ozempic and Zepbound, from unconventional sources. Doctors have safety concerns.

Glucagon-like peptide-1 receptor agonists improve cardiovascular outcomes and reduce mortality in patients with type 2 ...

Sales are booming for Lilly's tirzepatide products, Mounjaro and Zepbound. The company's market share for incretin analogs now tops 50%. Notably, Lilly's market share is increasing while Novo ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

GLP-1 receptor agonists remain blockbuster drugs for weight management for people with overweight or obesity. Increasingly, ...

Tirzapetide dose escalation schedules were slower in the real-world than clinical settings among individuals with obesity without T2D.

The filmmaker’s candid post opens a conversation about health, stigma, and promising advances in diabetes and weight ...

Available by prescription (Xenical) and over the counter (Alli), it is often used with a low-fat diet. While effective, ...

Community Oncology Conference empowered attendees with insights on advocacy, innovation, and practical strategies for ...